The Flow Cytometry Core provides flow cytometry research support for Center members. The Core endeavors to provide high quality multi-color analysis, high-speed sorting (including biohazard sorting), education, consultation, application development, and data analysis. The Core has changed dramatically since the 2003 review. Use has increased 50%. To accommodate and permit this increase the Core has increased both hardware and staff. We have added four analytical cytometers ~ three 9-color CyAns and an 18-color LSRII and two sorters ~ a digital MoFlo XDP and Reflection. The Reflection which is configured for BSL-2+ sorting has been placed in specially renovated BSL-2+ space. We have also upgraded the FACSCalibur and FACScan to dual-laser, 5-color instruments. We have added two highly skilled 1.00 FTE positions to accommodate the increased use and to provide additional services. Notably, the Core's staff has an aggregate of 77 years of flow cytometry experience. In sum the Facility provides state-of-the-art analytical and sorting flow cytometers, expertise, education, consultation, data analysis, and ease of access (domain and website, central data storage and archiving, web-based scheduling). The Flow Cytometry Core is directed by Dr. Larry Arnold, the Director since the inception of the Core In 1982. In 2009 152 laboratories used the Core;Center members accounted for 76% of total use. The CCSG budget request is for $141,810 representing a CCSG contribution of 23% to the total projected budget. The requested increase is to help establish the new biohazard sorting facility which for the first-time will permit sorting of viable human materials and other pathogen containing materials by Center members. Our future plans are to concentrate on education of users to increase their competency and, thus, data quality. Our single technology investment plan is to evaluate the utility of the Amnis ImageStream imaging flow cytometry technology for our users.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016086-37
Application #
8392170
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2012-12-01
Budget End
2013-11-30
Support Year
37
Fiscal Year
2013
Total Cost
$220,847
Indirect Cost
$72,664
Name
University of North Carolina Chapel Hill
Department
Type
DUNS #
608195277
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
Lianga, Noel; Doré, Carole; Kennedy, Erin K et al. (2018) Cdk1 phosphorylation of Esp1/Separase functions with PP2A and Slk19 to regulate pericentric Cohesin and anaphase onset. PLoS Genet 14:e1007029
Allott, Emma H; Geradts, Joseph; Cohen, Stephanie M et al. (2018) Frequency of breast cancer subtypes among African American women in the AMBER consortium. Breast Cancer Res 20:12
Dhungel, Bal Mukunda; Montgomery, Nathan D; Painschab, Matthew S et al. (2018) 'Discovering' primary effusion lymphoma in Malawi. AIDS 32:2264-2266
Cameron, Jennifer E; Rositch, Anne F; Vielot, Nadja A et al. (2018) Epstein-Barr Virus, High-Risk Human Papillomavirus and Abnormal Cervical Cytology in a Prospective Cohort of African Female Sex Workers. Sex Transm Dis 45:666-672
Lim, Joseph K; Liapakis, Ann Marie; Shiffman, Mitchell L et al. (2018) Safety and Effectiveness of Ledipasvir and Sofosbuvir, With or Without Ribavirin, in Treatment-Experienced Patients With Genotype 1 Hepatitis C Virus Infection and Cirrhosis. Clin Gastroenterol Hepatol 16:1811-1819.e4
Wang, Gary P; Terrault, Norah; Reeves, Jacqueline D et al. (2018) Prevalence and impact of baseline resistance-associated substitutions on the efficacy of ledipasvir/sofosbuvir or simeprevir/sofosbuvir against GT1 HCV infection. Sci Rep 8:3199
Phillips, Bonnie; Van Rompay, Koen K A; Rodriguez-Nieves, Jennifer et al. (2018) Adjuvant-Dependent Enhancement of HIV Env-Specific Antibody Responses in Infant Rhesus Macaques. J Virol 92:
Takaku, Motoki; Grimm, Sara A; Roberts, John D et al. (2018) GATA3 zinc finger 2 mutations reprogram the breast cancer transcriptional network. Nat Commun 9:1059
Galanis, Evanthia; Anderson, S Keith; Miller, C Ryan et al. (2018) Phase I/II trial of vorinostat combined with temozolomide and radiation therapy for newly diagnosed glioblastoma: results of Alliance N0874/ABTC 02. Neuro Oncol 20:546-556
Agle, Kimberle; Vincent, Benjamin G; Piper, Clint et al. (2018) Bim regulates the survival and suppressive capability of CD8+ FOXP3+ regulatory T cells during murine GVHD. Blood 132:435-447

Showing the most recent 10 out of 1525 publications